Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Pivotal Study of the Aptus Endovascular AAA Repair System (STAPLE-2)

This study has been completed.
Information provided by (Responsible Party):
Medtronic Endovascular Identifier:
First received: July 24, 2007
Last updated: October 7, 2016
Last verified: April 2016
Results First Received: April 21, 2016  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Abdominal Aortic Aneurysms (AAA)
Intervention: Device: Aptus Endovascular AAA Repair System

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
AAA Repair System Aptus Endovascular AAA Repair System: EVAR

Participant Flow:   Overall Study
    AAA Repair System
STARTED   155 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
AAA Repair System Aptus Endovascular AAA Repair System: EVAR

Baseline Measures
   AAA Repair System 
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Standard Deviation)
 73  (8) 
[Units: Participants]
Female   10 
Male   145 
Region of Enrollment 
[Units: Participants]
United States   155 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Effectiveness: Composite Success Rate   [ Time Frame: 12 months ]

2.  Primary:   Safety: MAE (Major Adverse Event)   [ Time Frame: 30 days ]

3.  Secondary:   Safety: SAE (Serious Adverse Event)   [ Time Frame: 5 years ]

4.  Secondary:   Effectiveness: Surgical Conversion   [ Time Frame: 12 months ]

5.  Secondary:   Effectiveness: Aneurysm Rupture   [ Time Frame: 12 months ]

6.  Secondary:   Effectiveness: Aneurysm Change   [ Time Frame: 12 months ]

7.  Secondary:   Effectiveness: EndoStaple Stent/Fracture   [ Time Frame: 12 months ]

8.  Secondary:   Effectiveness: Prosthesis Migration   [ Time Frame: 12 months ]

9.  Secondary:   Effectiveness: Type I Endoleak and Type III Endoleak   [ Time Frame: 12 months ]

10.  Secondary:   Effectiveness: Thrombosis   [ Time Frame: 5 years ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Kristin Schwartz
Organization: Medtronic Endovascular
phone: (763) 514-4000

Responsible Party: Medtronic Endovascular Identifier: NCT00507559     History of Changes
Other Study ID Numbers: 2007-01
Study First Received: July 24, 2007
Results First Received: April 21, 2016
Last Updated: October 7, 2016